SCHEMBL3038091

SCHEMBL3038091

C/C=C\CCCCCCO[C]=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR2 Q9HBW0 6/20 0.34
LPAR3 Q9UBY5 6/20 0.34
LPAR1 Q92633 3/20 0.34
SOAT1 P35610 1/20 0.31
TERT O14746 3/20 0.31
MAPT P10636 2/20 0.31
BLM P54132 2/20 0.31
HSD17B10 Q99714 2/20 0.31
FABP4 P15090 2/20 0.31
F7 P08709 2/20 0.31
F3 P13726 2/20 0.31
PTPN1 P18031 2/20 0.31
PPARG P37231 2/20 0.31
PPARD Q03181 2/20 0.31
PPARA Q07869 2/20 0.31
GMNN O75496 1/20 0.31
USP2 O75604 1/20 0.31
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3024776 1.00 LPAR2 (0.34) LPAR2LPAR3LPAR1SOAT1TERT
SCHEMBL95935 0.91
SCHEMBL95936 0.91
SCHEMBL97121 0.82
SCHEMBL97122 0.82
SCHEMBL3035571 0.82 LPAR2 (0.53) LPAR2LPAR3LPAR1MAPTBLM
SCHEMBL3031132 0.82 LPAR2 (0.53) LPAR2LPAR3LPAR1MAPTBLM
SCHEMBL2889638 0.82 FAAH (0.52) LPAR2LPAR3LPAR1TERTMAPT
SCHEMBL3029528 0.79 LPAR3 (0.42) LPAR2LPAR3LPAR1FAAH
SCHEMBL3045079 0.79 LPAR3 (0.42) LPAR2LPAR3LPAR1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216736-A2 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND TAIHO PHARMACEUTICAL CO., LTD. (JP) 2010-08-26 US disclosed
US-20100056466-A1 2'-Cyanopyrimidine Nucleoside Compound MATSUDA, AKIRA (JP) 2010-03-04 US disclosed
EP-2045256-A1 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) 2009-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216736-A2 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND NUDT1, DPYD, SLC29A1 LPAR2 2934/4885LPAR3 2306/4885LPAR1 2368/4885
US-20100056466-A1 2'-Cyanopyrimidine Nucleoside Compound NUDT1, DPYD, SLC29A1 LPAR2 2934/4885LPAR3 2306/4885LPAR1 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.